1. Growth hormone (GH) secretion from pituitary somatotropes is mainly regulated by two hypothalamic hormones, GH-releasing hormone (GHRH) and somatotrophin releasing inhibitory factor (SRIF). 2. Somatotrophin releasing inhibitory factor inhibits GH secretion via activation of specific membrane receptors, somatostatin receptors (SSTRs) and signalling transduction systems in somatotropes. 3. Fiv...

It is estimated that around 55-60% of men with prostate cancer will develop metastatic disease, most commonly involving bone. The initial treatment for metastatic disease is hormonal ablation, either with surgery (bilateral orchidectomy) or medically with gonadotrophin releasing hormone analogues such as goserelin, leuprorelin or triptorelin. A luteinising hormone-releasing hormone (LHRH) antag...

Androgen deprivation therapy (ADT) is key to the treatment of men with advanced prostate cancer. ADT can consist of surgical (bilateral orchiectomy) or medical strategies (eg, luteinizing hormone-releasing hormone agonists or gonadotropin-releasing hormone [GnRH] antagonists). The substantial reduction of testosterone levels achieved with ADT is associated with numerous well-characterized side ...

Androgen deprivation therapy (ADT) is one of the main treatments for patients with locally advanced and metastatic prostate cancer. ADT decreases level testosterone. Despite development new effective drugs in recent years, luteinizing gonadotropin-releasing hormone agonists are frequently administered as ADT. One most commonly used first-line triptorelin (Diferelin®). In Russia, usually receive...

Introduction: Gonadotropin-releasing hormone (GnRH) agonist triggers are increasingly used in antagonist vitro fertilization (IVF) cycles to prevent ovarian hyperstimulation syndrome (OHSS) following a robust response. The luteolytic effects of GnRH agonists inhibit implantation or spontaneous pregnancy, warranting freezing available blastocysts for future transfer after the risk OHSS subsides....